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For decades, interactions between the enteric neuromuscular apparatus and the central 
nervous system have served as the primary focus of pathophysiological research in the 
functional gastrointestinal disorders. The accumulation of patient reports, as well as clinical 
observations, has belatedly led to an interest in the role of various luminal factors and their 
interactions with each other and the host in functional gastrointestinal disorders. Most 
prominent among these factors has been the role of food. As a consequence, while not always 
evidence-based, dietary interventions are enjoying a renaissance in irritable bowel syndrome 
management. Not surprisingly, given its exploration in many disease states, the gut microbiota 
has also been studied in functional gastrointestinal disorders; data remain inconclusive. 
Likewise, there is also a considerable body of experimental and some clinical data to link 
functional gastrointestinal disorders pathogenesis to disturbances in epithelial barrier integrity, 
abnormal entero-endocrine signaling and immune activation. These data provide growing 
evidence supporting the existence of micro-organic changes, particularly in subgroups of 
patients with functional dyspepsia and IBS. However, their exact role in the complex 
pathophysiology and symptom generation of functional gastrointestinal disorders needs to be 
further studied and elucidated particularly with longitudinal and interventional studies.  
 
 








Though the focus of studies on the pathophysiology of functional gastrointestinal disorders 
(FGIDs) has been largely on the enteric neuromuscular apparatus and its central connections 
through the gut-brain axis, the potential importance of the luminal environment was noted 
many decades ago in the first descriptions of FGID-type symptoms developing de novo in the 
aftermath of an enteric infection.1 Clinical experience informed us of the importance of food as 
a symptom precipitant yet, up until very recently, little research had been performed on 
interactions with diet and/or the products of digestion in the FGID sufferer. As the complexities 
of the human microbiota are increasingly understood, the possibility that microbe-host 
interactions, including immune and metabolic responses, might be relevant to the FGIDs has 
emerged. How any one or a combination of these luminal factors interact with each other and 
with the host is a subject of considerable research interest and putative pathophysiological 
mechanisms have been postulated (Figure 1).  
These will be explored further in this review. Caveats that may limit the outcome of the present 
review must be acknowledged. Although we aim to refer to human studies, animal data could 
be mentioned when instrumental to better understand the role of microenvironmental factors in 
FGID. As most studies have been conducted in patients suffering from functional dyspepsia 
(FD) and irritable bowel syndrome (IBS), we will address only marginally other FGIDs. 
Pharmacological and other interventional approaches involving the intestinal 
microenvironment will not be systematically reviewed here.   
 
FOOD 
There is increasing recognition that dietary factors may play a major role in the etiology and 
the pathogenesis of symptoms in both FD and IBS. Their impact could be mediated through 
direct interactions between dietary components and mucosal receptors that may have been 
sensitized to these stimuli, or via down-stream events triggered by dietary components, such 
as the release of gut hormones, changes in epithelial morphology, the generation of immune 
responses or altered signaling between the gut and the brain. 
Dietary factors that reportedly trigger symptoms include eating patterns, as well as specific 
foods and/or food components. Only a few small studies have evaluated the direct effects of 
administering specific foods or nutrients on symptom provocation.  No intervention studies 
have evaluated the impact of targeted dietary changes on symptom improvement.  
Although patients with IBS have long associated their symptoms with food ingestion, a focused 
scientific and clinical interest in the potential role of food in IBS has emerged only recently. 
 
Role of Diet  
No major differences have been found in eating patterns between FD patients and controls, 
although limited evidence suggests that patients eat fewer meals per week, and tend to eat 
more smaller meals/snacks, than controls.2 While up to 80% of patients report that fatty 
foods/meals induce their symptoms, and ~30% exclude fried foods to avoid symptoms, many 
other foods are also reported to induce symptoms.3 Data on dietary nutrient composition in FD 
are limited and inconsistent; possibly because some patients modify their diets in an attempt to 
alleviate symptoms. The only available prospective study, in FD patients, noted trends towards 
lower fat and energy intakes and direct relationships between, on the one hand, postprandial 
fullness and fat and energy intake and on the other, between bloating and fat intake.2 Wheat- 
and carbohydrate-containing foods have been identified as triggers for symptoms, and FD 
patients frequently report symptoms on exposure to milk and dairy products, although their 
role remains unclear. Data on fiber intake in FD are inconsistent.  
The majority of IBS patients associate ingestion of a wide range of foods with symptoms, 
particularly abdominal bloating and pain.4 Patients frequently report making dietary 
adjustments, including reduced consumption of milk products, wheat products, alcohol and 
certain fruits or vegetables that are high in poorly absorbed short-chain carbohydrates and 
sugar alcohols (e.g. onions) and an increased intake of other fruits high in fermentable 
oligosaccherides, monosacherides and polyols (FODMAPs) (e.g. grapes and pears).5 Data on 
such dietary adjustments in IBS are not consistent. Many IBS patients report symptoms in 
  
Rome IV – Microenvironment & FGID 
5 
 
response to wheat-containing products, reminiscent of the sensitivity to gluten that 
characterizes celiac disease, despite negative celiac serology and normal small intestinal 
morphology; a phenomenon that has been termed “non-celiac gluten sensitivity” (NCGS). 
Subsets of patients also report symptoms following consumption of milk and dairy products, or 
spicy foods. The view that a lack of dietary fiber was the main cause of IBS has largely been 
revised.  While soluble fiber may have some beneficial effects, insoluble fibers, including bran, 
appear to be neither of benefit, nor harm. 
 
Provocation of Symptoms 
Prospective studies have only evaluated the effects of fat on symptoms. While equicaloric 
high-fat and high-carbohydrate yogurt-based meals both increased FD symptoms, pain, 
fullness and nausea were greatest after the high-fat meal.3  
Studies that manipulate dietary constituents provide further insights. Ingestion of a high-
FODMAP diet worsened symptoms (abdominal pain, bloating, excessive flatus) in patients, 
compared with healthy controls or a low-FODMAP diet. Moreover, in patients on a low-
FODMAP diet, blinded re-challenge with fructose and/or fructan, but not glucose, exacerbated 
symptoms.6  The role of gluten in IBS remains uncertain. While one recent study in patients 
with diarrhea-predominant IBS and “NCGS” found an improvement in symptoms on a gluten-
free diet, and their relapse when gluten was re-introduced in a blinded fashion, another study 
was unable to confirm gluten-specific, as distinct from FODMAP-related, effects on 
symptoms.7 In another study, exposure to gluten increased stool frequency and altered gut 
barrier function; mainly in IBS-D subjects who were human leukocyte antigen (HLA)-DQ2 or 
DQ8 positive. While some studies have found an improvement in symptoms on a milk- or 
dairy-free diet, these trials were often not blinded. Intolerance may also exist towards other 
components of milk. Acute ingestion of hot chili powder, in a capsule with a meal, increased 
abdominal pain and burning in IBS patients, compared with healthy controls.  
 
Potential Mechanisms 
The limited research that has been performed suggests that symptoms generated by food 
ingestion in FD may be due to exaggerated signals originating in the upper GI tract, including 
gastric hypersensitivity to distension, small intestinal hypersensitivity to fat, and 
hypersensitivity to the effects of gut hormones (particularly cholecystokinin), acid, capsaicin 
and the products of colonic fermentation.3 
Several factors could contribute to the pathophysiology of food-related symptoms. An 
enhanced phasic colonic motor response to food ingestion and colonic hypersensitivity to 
distension may both contribute to a non-specific increase in abdominal symptoms post-
prandially in IBS. FODMAPs are osmotically active and increase water content in the intestinal 
lumen. They are rapidly fermented to hydrogen (H2), carbon dioxide (CO2), methane (CH4), 
short chain fatty acids (SCFAs) and lactate. Such responses could be exaggerated in IBS; the 
resulting distension of the intestinal lumen may exacerbate visceral hypersensitivity. Gluten 
may cause a mild immune response in IBS patients, associated with exaggerated responses 
in enteric and sensory nerves and compromised intestinal barrier function.8 Some of the 
adverse reactions attributed to “gluten” may reflect a hypersensitivity to wheat or intolerance to 
FODMAPs. GI symptoms attributed to wheat (the largest dietary fructan source) may also 
relate to FODMAPs, rather than gluten.7, 8 Thus, the term “wheat intolerance or sensitivity” may 
be more appropriate than NCGS. A high prevalence of autoimmune disease amongst patients 
with wheat sensitivity has been described.9 Lipids may exacerbate IBS symptoms through 
modulation of distal gut motor functions and sensitivity. An increase in the density of sensory 
fibers expressing transient receptor potential cation channel, subfamily V (TRPV)-1 receptors 
in IBS patients with visceral hypersensitivity may enhance transmission of pain signals, 
including those generated by spicy foods. Recently a role for TRPV4 has also been proposed 
as a possible pathway of pain transmission in patients with IBS (see below).10 
 
Translational Research 
Prospective studies evaluating the effects of dietary interventions in FD are urgently required. 
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While recent studies have reported beneficial effects of a low-FODMAP diet on symptoms,11 
stool habits and quality of life, studies were small in size and further evidence is required to 
determine whether a low-FODMAP diet is better than a standard diet in controlling symptoms 
in IBS. Furthermore, the observed effects on the reduction of fecal commensal bifidobacteria, 
and detrimental effects on gut microbiota composition,12 require further investigation. A gluten-
free diet improves IBS symptoms and reduces bowel frequency and intestinal permeability.13, 
14 The gluten-specificity of these effects remains to be established. Comprehensive dietary 
counseling, including the adoption of healthy eating habits, avoidance of foods rich in 
FODMAPs, insoluble fiber and artificial sweeteners, replacing wheat with spelt products, and 
the importance of ingesting dairy products, has been reported to be associated with a 
significant reduction in IBS symptoms, including abdominal pain, diarrhea (in IBS-D) and 
constipation (in IBS-C), and a marked improvement in the quality of life.15 
 
THE MICROBIOTA AND ITS METABOLIC INTERACTIONS 
When food enters our intestine the undigested components are utilized by the intestinal 
microbes, collectively called the GI microbiota. The microbiota is dominated by bacteria 
belonging to the phyla Firmicutes, Bacteroidetes and Actinobacteria. These microbes inhabit 
the various regions in the GI tract of which the colon is most densely populated. The 
microbiota has a major impact, not only on processes that occur in the GI tract but also on 
systemic functions, and thus plays a key role in our overall health.  
 
Impact of Diet and Lifestyle on Microbiota 
It is evident that lifestyle and diet are crucial determinants of microbiota composition and 
function in humans. Comparative studies have demonstrated huge differences in microbiota 
composition between human populations in Western and those in developing countries and 
suggested that these are based on lifestyle and long-term dietary pattern differences.16 Short-
term dietary changes have also been shown to impact the composition of the microbiota. To 
date, such alterations have been shown in intervention studies which involve quite drastic 
changes in diets while more subtle, short-term dietary interventions have, in general, only a 
minor impact on the microbiota composition.17 The impact of diet on the microbiota may be 
direct, through changes in its composition or total energy supply, or indirect via the induction of 
changes in intestinal transit time or intraluminal pH. Of note, the impact of diet on the 
microbiota is also highly dependent on the intestinal location. For example, the conversion of 
complex indigestible carbohydrates is the driving force for the microbiota in the colon, while 
the microbiota in the small intestine is largely driven by the fast uptake and conversion of 
sugars that are likely derived from digested dietary polysaccharides.18  
 
Microbiota Metabolism of Dietary Substrates in Functional Gastrointestinal Disorders 
Carbohydrate 
Complex dietary components can be converted by the microbiota to a wide variety of 
metabolites which may involve cross-feeding and synthrophic interactions between individual 
microbes.17, 19 Which metabolites are produced and in what quantities, is dependent on the 
dietary components. The fermentation of complex carbohydrates, such as fibers and resistant 
starches, results, in general, in the production of short chain fatty acids (SCFAs), notably 
acetate, propionate and butyrate; on a Western diet approximately 300 mmol of SCFA are 
produced daily. Since SCFAs are fuels for our intestinal cells and serve as signaling 
molecules, they are considered as beneficial, particularly butyrate and propionate. Butyrate 
can be produced by a wide variety of bacteria, and most well-known are Faecalibacterium 
prausnitzii, Eubacterium rectale, Eubacterium hallii, and Roseburia intestinalis.19 Sources for 
butyrate production include sugars, lactate, acetate, as well as amino acids, such as lysine.20 
This allows butyrate producers to engage in metabolic cross-feeding interactions with 
organisms that convert complex food components. Propionate fermentation occurs via three 
distinct pathways, of which the succinate pathway is the most commonly utilized route in the 
gut, mainly performed by Bacteroides spp. and Veillonella spp.19  Acetate can be produced by 
a wide variety of microbes in the gut from fermentation of carbohydrates in a so-called mixed 
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fermentation with lactate or other SCFAs such as propionate. Acetate may also be generated 
via reductive acetogenesis, the reduction of carbon dioxide with H2, a process that is estimated 
to be responsible for one third of total acetate production in the intestine.  
A few human studies suggest a role for SCFAs in FGIDs and imply that nerves are involved. 
For example, a reduction in abdominal pain in IBS patients administered sodium butyrate was 
observed.21, 22 It was speculated that butyrate reduced the hypersensitivity of intestinal 
mechanoreceptors and altered neurotransmitter release, resulting in a reduction in luminal 
pressure and/or peristalsis.  Others have observed higher levels of acetic acid, propionic acid 
and total organic acids in IBS patients, with higher acetic acid levels being associated with 
greater GI symptoms.22, 23 
Carbohydrate fermentation also results in the production of H2 and CO2, which are the main 
intestinal gases formed in the intestine by the microbiota. Whereas impaired handling of 
intestinal gases has been consistently described in IBS, the contribution of the microbiota to 
this phenomenon is far from clear. H2 is thought to inhibit fermentation, but can also serve as 
an energy source for a variety of microbes, including methanogenic Archaea, reductive 
acetogens and sulfate reducers.17-19 The latter group produces sulfide, a toxic component that 
is regarded as harmful to our health. Potential sources of the required sulfate include dietary 
components and host-derived substrates, such as mucin (MUC). Although the relative 
volumes of intestinally derived gases excreted in the breath have been used to relate FGID 
symptoms to microbial fermentation rates in situ in the gut, this extrapolation is fraught with 
problems due to cross-feeding between different microbial populations, such as has been 
described above, resulting in altered relative concentrations of intestinal gasses that together 
determine the total volume.  
Relatively little data is available on qualitative changes in gas composition in FGIDs. Increased 
CH4 production in constipation predominant IBS-C24 is well known, but it is unclear whether 
this is a cause or effect. One study correlated CH4 with a higher motility index in IBS patients. 
25 24 Hydrogen Sulphide (H2S) signals through multiple pathways, including nerves, but human 
studies are lacking to demonstrate a role.  
Protein 
Protein utilization requires protease activity, which is available in both man and microbes. 
Although less frequently studied than carbohydrate fermentation, microbial fermentation of 
protein is, in general, considered as potentially harmful to health, since AA fermentation can 
lead to toxic products such as amines and ammonia as well as N-nitroso, indolic, sulfur and 
phenolic compounds.26 Potential sources of proteins for fermentation include diet and host-
derived compounds. Although most proteins are digested and taken up by the small intestine, 
a high-protein diet could lead to the arrival of significant protein loads in the colon. Since 
microbes favor carbohydrate fermentation over protein fermentation, it has been speculated 
that low carbohydrate diets may promote protein fermentation in the intestine.  
A recent study showed that concentrations of fecal proteases were higher in IBS-D patients 
compared to healthy controls, suggesting enhanced protein metabolism in the colon.27 
Remarkably, most of these proteases were of human origin. Nevertheless, it is conceivable 
that increased protease activity in the colon may lead to higher rates of AA fermentation. 
Fat 
Dietary fat content has also been negatively correlated with health status. In contrast, 
however, to carbohydrates and proteins, fat is not believed to reach the colon and be exposed 
to its microbiota in significant amounts since most is digested and absorbed in the small 
intestine. One indirect effect of dietary fat assimilation is its facilitation of the diffusion of 
bacterial components, such as lipopolysaccharide, across the epithelium, which could lead to 
low-grade inflammation, such as some have described in IBS. 28 
 
Microbiota Structure and Functional Gastrointestinal Disorders 
A recent report of the Rome Foundation on the microbiota in FGIDs provided an excellent 
overview of the importance of the microbiota in health and disease and, especially, in relation 
to FGIDs.29 Figure 2 provides a schematic representation on the role of the intestinal 
microbiota in conversion of dietary components and their potential impact on the 
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pathophysiology of FGIDs.  Several lines of evidence suggest the involvement of the intestinal 
microbiota in the pathogenesis of FGIDs in general and IBS in particular:  
1) gastrointestinal (GI) infections are strong risk factors for the development of FD and IBS 
(see below); 
2) fecal microbiota is substantially different in IBS and post-infectious IBS compared with 
healthy controls, and shows reduced microbiota diversity;29 
3) innate and adaptive immunity directed to microbiota-derived molecules, including the 
expression of toll-like receptors (TLRs) in the mucosa, the production of human beta 
defensin-2 and antibodies to bacterial flagellin are substantially different in IBS compared 
with controls;29 
4) some evidence indicates the existence of abnormal concentrations of fermentation end-
products, such as SCFAs, which may participate in symptom production in some patients 
with in IBS (see above); one recent study showed that total SCFA level was significantly 
lower in C-IBS patients than in D-IBS and M-IBS patients and healthy controls; 
5) case–control studies show that systemic antibiotic use is a risk factor for the de novo 
development of FGIDs;30 
6) in 43 RCTs the RR of IBS symptoms persisting with probiotics vs. placebo was 0.79 (95% 
CI 0.70-0.89), with positive effects on global IBS, abdominal pain, bloating, and flatulence 
scores.31  
Nonetheless, major limitations still hamper the definition of the role of the microbiota in FGIDs. 
Indeed, there is no consensus on the nature of the microbial signatures that may be 
consistently (either positively or negatively) correlated to FGIDs. These inconsistencies may 
relate to several factors, including: 1) methodological differences, 2) variations in sample 
sources, 3) intrinsic variability between subjects, 4) differences in subject selection and 
definition of study populations, 5) overlap between the various FGIDs, and 6) differences in 
diet, therapy or other environmental exposures. It needs to be recognized that many studies 
described comparisons between different groups of subjects on the basis of a single fecal 
sample per subject, which only represents a snapshot of the microbiota and, as a result, such 
comparative analyses cannot differentiate between cause, consequence or coincidence. Given 
the large heterogeneity in the human population and the extent of microbial diversity, it is likely 
that many significant correlations are just coincidence. This may, in part, explain why there has 
been no consensus regarding whether a specific microbe or groups of microbes is associated 
with a given FGID.29 Therefore, it is evident that longitudinal studies, involving repeated 
sampling of the microbiota, will be crucial to differentiate cause from consequence or 
coincidence. Such studies could include interventions with dedicated diets or dietary 
supplements, specific pharmacological interventions, or novel therapies such as fecal 
microbiota transplantation.  
 
BILE ACIDS 
Bile acids (BAs) play a central and critical role in the digestion and absorption of fat and fat-
soluble vitamins, and a highly efficient enterohepatic circulation ensures the conservation of 
secreted BAs; the primary means of BA conservation being active absorption via the apical 
sodium-dependent ileal BA transporter (IBAT) located on the apical surface of ileal 
enterocytes. BA absorption and secretion are closely linked through a feed-back loop which 
involves a number of receptors and mediators which ultimately impact on the rate-limiting 
enzyme in BA synthesis (Figure 3).32 
BAs have a variety of physiological effects of relevance to the FGIDs; on motility, intestinal 
secretion, membrane permeability and visceral sensation33 and act as important signaling 
molecules with effects well beyond the GI tract. As BAs repress bacterial growth in the 
intestine, the development of microbial enzyme pathways capable of deconjugating and 
transforming BAs is an important adaptive response by commensal bacteria.34 In contrast, 
anti-bacterial and mucosal immune-stimulating effects of BAs play an important role in the 
prevention of small intestinal bacterial overgrowth (SIBO). 35 
Human physiological studies suggest a role for luminal BA signaling to enteric nerves in 
causing altered small bowel motility and increased sigmoid and rectal motility.  In IBS-D, it was 
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estimated that as many as 10% of patients malabsorb BAs36 37 and infusion of BAs in the 
colon disproportionately stimulated motility compared to controls. In idiopathic BA 
malabsorption (BAM),38 phase III-induced neurogenic secretions were increased in the 
jejunum and prostigmine increased the colonic motility index, implying involvement of the 
enteric nervous system39.  Genetic variants of the G protein-coupled bile acid receptor 
(TGR5) , found on multiple cells including enteric nerves, have also been linked to transit time 
in patients with FGIDs.37  Altered metabolism of BAs by colonic bacteria might also be 
involved, as constipation and increased transit time correlated with a reduction of colonic BAs, 
possibly the result of bacterial sulfation.40   
 
EPITHELIUM AND MUCOSAL BARRIER 
The intestinal luminal-mucosal interface represents the first location where toxic and 
immunogenic particles face the scrutiny of the mucosa-associated immune system. Loss of 
molecular and functional integrity of the epithelial barrier could lead to activation of mucosal 
immune responses and set in motion events that are closely related to the origin and clinical 
manifestations of several FGIDs. 
 
Molecular Structure 
The apical junctional complex keeps enterocytes tightly sealed and regulates paracellular 
permeability.41 This complex is composed of tight junctions (TJs), adherens junctions and 
desmosomes. Intracellular (zonula occludens (ZO)-1, ZO-2 and ZO-3, and cingulin) and 
surface-membrane proteins (occludin, claudins, and junctional adhesion molecules (JAMs)) 
are major components of TJs.41 Adherens junctions are mainly composed of e-cadherin, 
catenin and actin filaments.41 Occludin seems to regulate the integrity of TJs while claudins 
determine their strength, size and ion selectivity, and JAMs their construction and assembly.42 
All are linked to actomyosin fibers by members of the ZO family and, in this way, control the 
opening/closing of TJs at paracellular spaces.43 Zonulin transactivates the epithelial growth 
factor receptor via proteinase activated receptor 2 (PAR2) activation and reversibly regulates 
intestinal permeability.  
 
Intestinal Permeability and Barrier Dysfunction 
The passage of molecules across the epithelium takes place mainly via two distinct routes: 1) 
the paracellular pathway, which allows small molecules (< 600Da) to diffuse through TJs and 
2) the transcellular pathway, which facilitates the transit of larger particles via the processes of 
endocytosis or exocytosis. Rapid changes in permeability usually occur via myosin light chain 
kinase (MLCK)-mediated cytoskeleton contraction and endocytosis of TJ proteins. In contrast, 
more sustained changes in permeability involve the transcriptional modulation of TJ proteins, 
epithelial cell apoptosis and ultrastructural alterations in the epithelium.41 
Acute stress either reduces net water absorption or increases jejunal secretion in healthy 
subjects through the parasympathetic nervous system and mast cell (MC) activation.44 
Moreover, higher background levels of stress have been related to decreased water secretion 
in healthy female volunteers exposed to cold pain stress.45 Stronger stresses, like abdominal 
surgery, GI infections, hemorrhagic shock or intensive exercise, increase intestinal 
permeability. Corticotropin releasing factor (CRF) enhances transcellular uptake of 
macromolecules in the human colon via CRF-R1 and CRF-R2 receptors on sub-epithelial 
MCs.46 Acute psychological stress also increases small intestinal permeability in humans; 
peripherally-administered CRF reproduces this effect and MC stabilization blocks the effects of 
both stress and CRF.47  
In-depth reviews on the role of physiological and pathophysiological stimuli controlling gut 
barrier have been recently published.41, 48 Vasoactive intestinal polypeptide regulates chloride 
secretion, MUC release, and paracellular permeability, partly through a direct effect on ZO-1. 
Substance P stimulates the release of pro-inflammatory cytokines and vasoactive mediators 
by macrophages, eosinophils, and MCs, contributing to chloride secretion, increased intestinal 
permeability and vascular leakiness. Nerve growth factor (NGF) has been involved in nerve- 
and mast cell-mediated, stress-induced barrier dysfunction. Both progesterone and estradiol 
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have been shown to reduce chloride secretion in intestinal epithelial cells whereas estradiol 
reinforced epithelial permeability and up-regulated JAM-A and occludin expression. Other 
mediators including CRF, leptin, and CCK may increase permeability while insulin-like growth 
factor, ghrelin, KdPT and glucagon-like peptide 2, may decrease intestinal permeability. 41, 48 
Various strains of Vibrio cholera, Clostridium difficile and toxin producing strains of Escherichia 
coli have shown to enhance intestinal permeability through direct TJ disruption, the production 
of toxins or proteases and the activation of the inflammatory cascade. In contrast, probiotics 
promote barrier integrity by increasing occludin, claudin 3, and ZO-1 and ZO-2 expression.49  
Interferon (IFN)-γ and tumor necrosis factor (TNF)-α induce barrier dysfunction through MLCK 
and claudin-2 up-regulation and down-regulation of occludin. Many other cytokines and 
proteases have effects on barrier function including interleukin (IL)-3, IL-4, IL-17, IL-22, and IL-
26, IFN-α, IFN-β, and transforming growth factors-α, and -β.50 
These aspects have been recently reviewed.48 In predisposed individuals, gluten and other 
specific food components may lead to increased intestinal permeability through the zonulin 
pathway and MC-mediated enhancement of both passage routes. Whey proteins may improve 
barrier function by a transforming growth factor β-mediated increase in intestinal claudin-4 
expression. Other nutritional products such as glutamine, butyrate, arginine, fatty acids, and 
prebiotics have been shown, to some extent, to exert a protective effect on the intestinal 
barrier.  
Ethanol promotes separation of ZO-1 proteins, disassembly of actin and myosin filaments and 
MLCK activation. NSAIDs, methotrexate, tacrolimus, omeprazole, and corticosteroids may 
also enhance intestinal permeability whereas heparin, vitamin D, and larazotide may decrease 
permeability. 
 
Mucosal Barrier and Functional Gastrointestinal Disorders  
There is little information on the status of mucus production in IBS other than isolated reports 
on the potential beneficial effects of probiotics or mesalazine on mucus quality and production, 
higher levels of trefoil factor 3 in the urinary IBS proteome, and increased expression of genes 
involved in the production MUC20 in the colon of IBS.  
Enhanced intestinal permeability has been reported in FD and in subsets of patients with IBS 
(Table 1, Supplementary material) and linked to alterations in JAM-A, ZO-1, e-cadherin, 
claudins and occludin (Table 2, Supplementary material), and these changes associated to 
MC activation and clinical manifestations.  
 
ENTEROENDOCRINE SYSTEM 
The entero-endocrine system, the largest endocrine organ, constitutes 1% of the gut 
epithelium. Fourteen cell populations including enteroendocrine cells and enteric nerves 
produce transmitter substances that signal to neighboring cells (paracrine), distant targets via 
the vascular system (endocrine) or through intrinsic/extrinsic nerves (neurocrine). These 
effector targets, in turn, control gut motility, secretion, sensation, absorption, vascular tone, 
microcirculation, immunity and cell proliferation (Figure 4; Table 3, Supplmentary material). 51-
53  
Serotonin Metabolism and Receptors 
Serotonin (5-hydroxytryptamine, 5-HT), is a paracrine/neurocrine amine primarily contained in 
the gut (95%) and only minimally in the brain (5%). Serotonin is synthesized from tryptophan, 
in enterochromaffin cells (EC) (90%) and authonomic nerves (10%).54, 55 Synthesis and 
release of serotonin involves conversion of dietary tryptophan to 5-hydroxy-L-tryptophan 
(catalyzed by tryptophan hydroxylase [TpH], isoforms, TpH1 [in gut] and TpH2 [in brain]),55-57 
granular packaging by vesicular monoamine transporter 158 and release, mainly determined by 
bowel wall distension, mucosal stroking, food, AAs, hypo- or hyper-osmotic solutions, glucose, 
galactose, adenosine, cholera toxin and chemotherapeutic agents.58, 59 SCFA, which may be 
produced in increased amounts by intestinal microbiota fermentation of carbohydrate 
substrates, may also promote the release of serotonin.58 An alternative metabolic pathway 
leads to the production of kynurenic acid (KYNA), and not serotonin, from tryptophan, and 
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results in reduced serotonin synthesis.60 The serotonin re-uptake transporter (SERT) 
terminates serotonin action (Figure 4).56  
In the gut, serotonin stimulates intrinsic primary afferent neurons (IPANs), which synapse in 
myenteric plexus with ascending and descending inter-neurons to evoke motility- and 
secretion-induced reflexes and also transmitting information to the brain.54, 56, 61  
 
Serotonin Metabolism in Functional Gastrointestinal Disorders 
SERT hyperactivity may lead to increased reuptake of serotonin, hence reducing the effects of 
the amine on target tissues. In contrast, hypofunction of SERT may increase serotonin 
concentrations leading to gut hypercontractility, hypersensitivity, diarrhea and pain.59 56 
Accordingly, in cell lines, infection with enteropathogenic E. coli reduced SERT activity.62 The 
SERT protein is encoded by a gene on chromosome 17q11 and is composed of 14 exons 
encoding 630 amino acids. Insertion/deletion of 44 base-pairs in 5-HT-transporter-gene-linked 
polymorphic region (5-HTTLPR), leading to reduced SERT expression, has been reported in 
IBS-D.63 5-HTTLPR (S/L) was more common than the S/S polymorphism in FD, particularly in 
the post-prandrial distress syndrome (PDS).64 In an Indian study, solute carrier family 6 
(neurotransmitter transporter), member 4 (SLC6A4)-polymorphism and higher levels of 5-HT 
were associated with IBS, particularly post-infectious IBS and IBS-D.65 The homozygous S 
genotype (reducing SERT expression) was more common in IBS-D.63 A meta-analysis on 25 
studies including 3443 IBS patients and 3359 controls, showed that the 5-HTTLPR mutation 
was associated with IBS-C but not with IBS-D and IBS with mixed bowel habit (IBS-M), and, 
particularly, among East Asians.66 More studies are needed to clarify this issue. 
The implication of serotonin in FGID has been previously reviewed. 58, 67 Data suggest that 
subgroups of patients with FGIDs show altered serotonergic signaling (Figure 4). Accordingly, 
the epigastric pain syndrome (EPS) subtype may have higher basal serotonin levels.64 In 
contrast, some data suggest that subsets of patients with FD may have low basal and 
postprandial plasma levels of serotonin.68 Studies suggest that IBS-D is associated with 
elevated, and IBS-C with reduced, serotonin plasma levels.58, 69 In one study, both serotonin 
and KYNA levels were lower in the duodenal mucosa and higher in plasma in IBS, than 
controls, suggesting a contribution from the KYNA pathway.60 As chili ingestion increases 
FGID symptoms and granisetron, a 5-HT 3-receptor antagonist, prevents it, serotonin is 
suggested as the mediator of chili-induced symptoms.70 Though a low FODMAP diet has been 
shown to improve IBS symptoms,12 data on its effect on brain and gut serotonin levels are 
lacking.  
In post-infectious IBS (see below), altered EC cells number has been reported.59 71 PI-IBS 
patients had higher rectal mucosal serotonin than non-PI IBS-D and non-diarrheal IBS. The 
entero-endocrine and immune systems are widely interconnected as suggested by the 
proximity of immune cells to EC cells.58, 67 Furthermore, immune cells, including B and T 
lymphocytes, monocytes, macrophages, and dendritic cells express serotonergenic receptors 
and mast cells, macrophages, and T cells synthesize serotonin from tryptophan.58 Serotonin is 
chemotactic for dendritic cells, mast cells and eosinophils and may participate in the 
recruitment of these immune cells in the intestinal mucosa (see below).58 Low-grade 
inflammation, such as has been detected in FGIDs may, in turn, contribute to altered serotonin 
synthesis and reuptake through changes in SERT expression.72 73 Th1 responses generate 
IFN-γ and TNF-α which inhibit SERT; Th2 responses, such as occur in parasitic infestations, 
stimulate IL-13, which increases EC numbers and TNFα, and also, therefore, inhibit SERT.74  
Efficacy for serotonergic agents, such as 5-HT3 receptor antagonists (alosetron, cilansetron, 
and ondansetron), including a large multicenter trial on ramosetron in female IBS-D patients 
with promising results,75  and 5-HT4 agonists (cisapride, tegaserod and prucalopride) in the 
treatment of IBS-D and IBS-C, respectively, also provide evidence for a role for serotonin in 
the pathogenesis of FGIDs.55, 56 
 
IMMUNE SYSTEM AND NEURO-IMMUNE INTERACTIONS 
Post-Infectious Functional Gastrointestinal Disorders  
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The observation that FD and IBS can develop following an episode of acute infectious 
gastroenteritis supports the involvement of the immune system in the pathophysiology of 
FGIDs. The mean incidences of post-infectious (PI)-FD and PI-IBS following infection with 
diverse pathogens (bacteria, parasites or virus) are 9.6% and 10%, respectively, with an 
overall OR of 2.5 for the presence of a FGID at six months post-infection compared to 
controls.31 76 Risk factors for PI-IBS include the severity and duration of the acute infection, 
female gender and psychological co-morbidity (e.g., hypochondriasis, neuroticism, depression, 
adverse live events, perceived stress, negative illness beliefs77), smoking, being a child at the 
time of the infection78  (Figure 5). The pathogenesis of post-infectious FGIDs is multifactorial 
and involves both pathogen and host factors.77 In PI-IBS, the colorectal mucosa shows 
increased infiltration of macrophages, mast cells and intraepithelial lymphocytes as well as 
PYY-containing enteroendocrine cells.71, 77 The association of the TNFα SNP rs1800629 with 
PI-IBS supports the hypothesis of a genetic predisposition possibly contributing to increased 
epithelial permeability and an inability to resolve an acute inflammatory process. 79 
 
Mucosal Immune Activation  
Numerous studies have shown increased numbers of mucosal immunocytes (i.e., mast cells, 
eosinophils and T cells) in adult and pediatric patients with FD and IBS. Several participating 
factors have been claimed, including food allergy, an abnormal microbiota, BAM, and 
increased intestinal permeability. The magnitude of the inflammatory response is several-fold 
less than that seen in acute inflammation in inflammatory bowel disease (IBD). The wide 
overlap with healthy controls, possible geographic and dietary variation and lack of 
methodological standardization might explain the failure of some studies to confirm the 
presence of increased immune cells in FGIDs. The nature of the inflammatory process is also 
different from that seen in acute GI inflammation in IBD, with no involvement of neutrophils or 
frank tissue distortion.29, 80 Eosinophils, usually linked to allergic reactions, have been 
associated with PDS and early satiety.81, 82 Increased mast cell numbers have been detected 
in the stomach and duodenum of patients with FD,82 in the esophagus of patients with non-
cardiac chest pain83 and throughout the gut in IBS-D and IBS-C,84 particularly in females, in PI-
FD and PI-IBS (for review, see 80). Genetic factors such as the TNFα rs1800629 genotype79 
have also been implicated. Microbial molecular pattern-mediated activation of innate immunity 
suggests a pathogenic contribution of the gut microbiota.85 TLRs are expressed on human 
submucosal and myenteric neurons86-88 and altered TLR expression has been observed in IBS 
tissues.  For example, TLR4 expression in colonic mucosal biopsies from IBS patients was 
increased, particularly in those with IBS-A.89 TLRs 5 and 2 were also upregulated, while TLRs 
7 and 8 were downregulated,89 85 Biopsy studies have provided evidence of epithelial 
permeability changes in IBS patients and bacterial proteases may play a role.90 Thus, in some 
IBS patients there may be increased expression of TLRs and/or a disruption of the mucosal 
barrier and increased bacterial translocation resulting in increased TLR signaling and/or an 
abnormal immune response to luminal microbes.85, 89 
 
Impact of Immune Activation on Gut Sensorimotor Function  
Supernatants obtained following incubation of mucosal biopsies from IBS subjects contained 
increased amounts of histamine, serotonin, polyunsaturated fatty acid metabolites 80 and 
proteases, including tryptase, trypsin.10 The exact source of proteases remains unclear; they 
may originate from mucosal mast cells, gut bacteria91 or pancreatic secretions.27 In adoptive 
transfer experiments, biopsy supernatants from IBS subjects evoked abnormal functional 
responses in enteric and sensory nerves of recipient rodents92-94 and human tissues.95 These 
effects were, at least partly, related to immune and endocrine factors, including proteases, 
histamine and serotonin.72, 92, 94  Application of biopsy supernatants to human or rodent tissues 
suggests that, in IBS, serine proteases, or PUFA metabolites, act respectively on PAR 
receptors92 and TRPV-4 10, to mediate visceral pain. In addition to these acute effects, a recent 
study suggested that the chronic release of immune metabolites could affect the structure of 
mucosal neural networks in IBS, i.e. increased neuronal density and outgrowth, as well as 
increased expression of mast cell NGF in the colonic mucosa of patients with IBS compared 
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with controls. 96 Mucosal supernatants of patients with IBS evoked increased neurite growth 
and expression of GAP43 (a key neuronal growth protein), when applied to primary cell 
cultures of rat myenteric plexus or to neuroblastoma cell line SH-SY5Y cultures. 96  
Probiotics may have beneficial effects in IBS, through the modulation of immune function. 
Indeed, Bifidobacterium infantis 35624, but not strains of Lactobacillus salivarius, was able to 
reduce a systemic pro-inflammatory cytokine profile along with symptom improvement97.  
 
Immune Activation and Symptoms 
Though several studies have demonstrated intestinal immune activation in FGIDs, reports of 
correlations with symptoms have been limited. Correlations were found between colonic mast 
cell density close to nerves and abdominal pain and bloating, and between bowel habit 
dissatisfaction, global IBS symptoms and circulating T cells.84, 98, 99 In addition, immune 
activation featuring increased small bowel homing T cells has been associated with the 
intensity of pain, nausea and vomiting in FD.100 Mucosal mast cells were associated with 
fatigue and depression, suggesting the potential role of psychological factors in the brain-gut-
immune axis in IBS.  
 
IMPLICATIONS FOR MANAGEMENT 
Diet and Food Components 
Food has long been recognized as an important precipitant of symptoms in FD and IBS. 
Exaggerated GI and colonic electrophysiological and motor responses to food ingestion have 
been extensively documented and a variety of hypotheses have been advanced to explain 
these responses, particularly in IBS. This process has also generated various diagnostic 
strategies which will be briefly reviewed here. 
Food Allergy  
Though up to 20% of the population and much higher proportions of IBS patients are 
convinced that they are allergic to certain foods and this is a major contribution to their 
problem, food allergy, traditionally denoted by an activation of IgE-mediated antibodies to a 
food protein, has not been linked convincingly to IBS pathogenesis and the status of IgG-
based testing remains unclear.101 Although confocal endomicroscopy studies suggests the 
existence of rapid morphological and functional changes in the epithelium and immune system 
of the small intestine after challenge with foods to which the patients reported intolerance, and 
symptomatic improvement following avoidance of these foods, this approach seems to be too 
cumbersome to be applied on a large scale.102       
Food Intolerance  
The contribution of lactose maldigestion to IBS depends on the prevalence of lactose 
maldigestion in the population studied. Furthermore, subjective reports of lactose intolerance 
correlate poorly with formal tests of lactose malabsorption rendering such tests of limited value 
in the evaluation of IBS.103 Lactose intolerance should be identified in patients with FGID and 
milk products avoided accordingly.  
Though IBS subjects appear, both subjectively and objectively, to be intolerant of fructose104, 
formal tests of fructose malabsorption failed to discriminate between IBS subjects and healthy 
controls.105 Again, it does not seem possible to recommend testing in IBS or other FGIDs nor 
extensive elimination diets prescribed.  
Sorbitol intolerance has also been reported in IBS and it is likely that sorbitol has an additive 
effect to fructose, with further exacerbation of symptoms.105 Here again rates of intolerance 
and malabsorption do not tally, thereby, limiting the value of diagnostic testing or dietary 
advice.  
Gluten intolerance/sensitivity  
The relationships between celiac disease, “gluten-sensitivity” and IBS remain unclear with 
various studies reporting increased106 or expected107 rates of celiac disease among IBS 
subjects. The status of that entity which has come to be referred to as NCGS108 is particularly 
unclear. Other than excluding celiac disease, and provide evidence of intolerance following 
double blind challenge, there are no currently validated diagnostic methods for diagnosing this 
entity. 
  




The Microbiota and its Metabolic Interactions 
SIBO, Fecal and Colonic Mucosal Microbiota  
The status of small intestinal bacterial overgrowth in IBS remains highly controversial. Two 
factors contributing to variations in prevalence of SIBO among IBS subjects have been the test 
modality and diagnostic criteria used to diagnose SIBO.109 While some patients with SIBO may 
present with IBS-type symptoms, it does not appear that SIBO is a major contributor to the 
pathogenesis of IBS, in general.110 The lactulose breath test has shown poor diagnostic 
performance to detect SIBO. While the glucose breath test performs slightly better, routine 
testing for SIBO cannot be currently recommended.29  
Though abnormalities in the fecal and colonic microbiota have been identified among IBS 
subjects and microbial signatures associated with certain demographic and etiological features 
in IBS, a fecal or mucosal microbial signal diagnostic of IBS or of an IBS sub-type or sub-
population has yet to be validated.29 Approaches aimed at modifying the microbiota, mainly 
with probiotics and non-absorbable antibiotics are now widely applied in clinical practice, 
particularly in patients with IBS, however, several questions remain to be elucidated, including, 
type of probiotics, dosage, relevant subgroups, therapeutic gain over placebo, treatment and 
retreatment schedules, as well as mode of action.29  
Bile Acids 
Abnormalities in fecal BAs, as well as in serum markers of BA synthesis, have been reported 
in a sub-group of IBS-D,111 and BAM may be responsible for a significant proportion of those 
with IBS-D.112 The 23-seleno-25-homo-tauro-cholic acid (SeHCAT) test, the most widely 
employed and validated test for the diagnosis of BAM, is not universally available. Alternate 
approaches include the measurement of fecal BAs, or serum levels of 7 α-hydroxy-4-
cholesten-3-one (C4), or a therapeutic trial of a bile salt sequestering agent.33, 40 
 
Epithelium and Mucosal Barrier 
The usefulness of measures of barrier integrity (such as the lactulose-to-mannitol excretion 
ratio) in the diagnosis or assessment of FGIDs has not been established,113 nor have the 
diagnostic role of ex vivo approaches on biopsies (Ussing chambers) and assays for molecular 
markers or surrogates of altered permeability (eg, endotoxin, anti-LPS antibodies, bacterial 
lactate, butyrate production, hemolysin test).48, 113 The role of endoscopic endo-microscopy 
detecting rapid functional/structural mucosal changes following challenge with food allergens, 
although attractive, remain to be confirmed in future studies.102 Strategies to modify mucosal 
permeability include the use of probiotics and dietary interventions although there is still 
uncertainness on the potential benefits. 48 
 
Enteroendocrine System 
While changes in basal or stimulated levels of a number of enteric hormones and 
neurotransmitters (such as post-prandial levels of 5-HT) have been described in IBS and other 
FGIDs, and manipulations of 5-HT metabolism have been shown to provoke symptoms, none 
have achieved the status of a diagnostic test. The use of drugs acting on serotonin agents 
remains a field of interest, now generating new potential therapeutic approaches for IBS-D 
with the study of older products with a new indication (eg, ondansetron)114 or newer products 
(eg, ramosetron)75 being tested in large clinical trials.  
 
Immune System and Neuro-Immune Interactions 
That the engagement between luminal contents on one hand and the microbiota and the 
immune system on the other hand might be relevant to the pathogenesis of IBS is suggested 
by studies documenting the up-regulation of immune biomarkers and various members of the 
Toll receptor family in this disorder. However, given the variability in results between studies it 
is not possible at this time to employ measures of the mucosal or systemic responses in the 
diagnosis of an FGID or in the delineation of a subgroup thereof.115 Two recent large placebo-
controlled studies in IBS patients showed that mesalazine was not clinically superior over 
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placebo, although both studies suggested that subgroups, including PI-IBS, showed sustained 
responses.  116, 117 
With respect to gases released in the process of bacterial fermentation it should be noted that 
with some, but not complete, consistency, the detection of methane in the breath has been 
linked to the predominance of constipation in IBS.118 The therapeutic implications of these 
findings remain unclear.  
 
CONCLUSIONS AND FUTURE DIRECTIONS 
While the role of food and dietary components is, at last, attracting the attention it has long 
deserved, many questions persist. While dietary studies are challenging, only large-scale, 
prospective studies using validated instruments can provide much needed information on the 
food habits of FGID subjects and also address such questions as to what extent dietary 
preferences in FGID subjects reflect the subconscious exclusion of items to which they are 
intolerant. Of the multiple factors that have been proposed, intolerance to poorly absorbed 
dietary carbohydrates has emerged as a major contributor in IBS with the status of true food 
allergy and gluten sensitivity remaining unclear. Different mechanisms may be relevant to 
various subjects or subject groups. Long-term studies of dietary interventions will be important 
by defining, not just their beneficial effects on symptoms, but also identifying any negative 
consequences. 
Though some tantalizing findings have been reported, studies of the gut microbiota and the 
host immune response in FGIDs have yielded variable and sometimes conflicting results: there 
is a need for longitudinal studies that include functional profiling of the microbiota, its 
metabolites (including gases and SCFAs) and related immunological responses in well-
characterized IBS populations. Such information will be critical to guiding therapeutic 
strategies that aim to modulate the microbiota, its products and/or the immune response.  
The signal transduction mechanisms that generate responses to BAs need to be delineated; 
i.e. whether they are receptor mediated, or generated by paracrine or non-specific effects. 
Above all, in relation to BAs, the current paucity of human studies needs to be addressed. 
Furthermore, microbiota-BA interactions in FGIDs need to be explored. 
While functional and molecular alterations of factors involved in intestinal permeability may 
explain IBS pathophysiology and symptom generation and could yield innovative biomarkers 
valuable in both diagnosis and the assessment of therapeutic response in FGIDs, further 
studies, using validated and preferably non-invasive markers, are needed to more precisely 
define the mechanisms and functional consequences of these alterations and their primacy in 
a given FGID.  
Well-designed studies on large numbers of patients and controls evaluating the 
enteroendocrine system, including changes in serotonergic responses, are also lacking in 
patients with FGIDs. Moreover, dietary, behavioral, pharmacological and gut-microbiota-
directed manipulations of entero-endocrine responses are likely to be important approaches to 
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FIGURE LEGENDS  
Figure 1. Schematic representation of the putative interplay between luminal and mucosal 
factors in FGIDs. Microenvironmental factors (e.g., food, microbiota, bile acids) may permeate 
in excess through a leaky epithelial  barrier allowing amplification of signaling from the lumen 
to deeper mucosal and muscle layers, including overstimulation of the mucosal immune 
system. These factors may determine abnormal signaling to neural circuits (intrinsic primary 
afferent nerves and extrinsic primary afferent nerves), which in turn may affect intestinal 
physiology and sensory perception.   
 
Figure 2. Overview of dietary components and metabolites produced in the GI tract, and their 
association with irritable bowel syndrome or its symptoms. *means increased levels in irritable 
bowel syndrome patients. Increases in CH4 and H2 concentrations contribute to bloating and 
distension and intraluminal concentrations of bile acids and proteases will promote diarrhea. 
Irritable bowel syndrome (IBS); irritable bowel syndrome with diarrhea (IBS-D); irritable bowel 
syndrome with constipation (IBS-C); branched chain fatty acids (BCFAs).  
 
Figure 3. Schematic representation of the interactions between the microbiota and bile acids 
as illustrated by a comparison of germ-free and normally colonized animals. The scheme 
shows increased activity and expression of cholesterol 7α-hydroxylase and levels of taurine-
conjugated β-muricholic acid in germ free mice. In contrast, the expression and activity of 
sterol 12α-hydroxylase and cholic acid levels are similar in germ free and normally colonized 
mice. Taurine-conjugated β-muricholic acid is a natural antagonist of the farnesoid X receptor, 
which, in turn, may elicit reduced inhibition of rate-limiting enzyme cholesterol 7α-hydroxylase 
in germ-free animals mice. In contrast, normally colonized animals, show a reduction in 
taurine-conjugated β-Muricholic Acid. This leads to increased activation of farnesoid X 
receptor in enterocytes, thus upregulating the fibroblast growth factor 15, which in turn 
suppresses cholesterol 7α-hydroxylase in the liver. In addition, the microbiota affects intestinal 
bile acid metabolism and increased their excretion. bile acyl-CoA synthetase (BACS); 
cholesterol-4 (C4); cholesterol 7α-hydroxylase (CYP7A1); cholic acid (CA); fibroblast growth 
factor receptor 4 (FGFR4); fibroblast growth factor 15 (FGF15); farnesoid X receptor (FXR); β-
muricholic acid (β-MCA); taurine-conjugated cholic acid (TCA); deoxy cholic acid (DCA); 
lithocholic acid (LCA); sterol 12α-hydroxylase (CYP8B1); taurine-conjugated β-Muricholic Acid 
(TβMCA). Reproduced with permission from 119 
 
Figure 4. Mechanism of action of serotonin and its re-uptake in irritable bowel syndrome. 5-HT, 
serotonin; acetylcholine (ACh); gamma amino butyric acid (GABA); irritable bowel syndrome 
(IBS); irritable bowel syndrome with diarrhea (IBS-D); Irritable bowel syndrome with 
constipation (IBS-C). 
 
Figure 5. Post-infectious IBS and related risk factors. Relative risk (RR). 
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